Pressmeddelanden från Hansa Biopharma

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Hansa Biopharma

Hansa Biopharma rapporterar finansiella resultat för första kvartalet 2026 23 apr 07:00

Hansa Biopharma

Hansa Biopharma Report First Quarter 2026 Financial Results 08 apr 17:00

Hansa Biopharma

Hansa Biopharma to host Q1 2026 interim results conference call 08 apr 17:00

Hansa Biopharma

Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2026 26 mar 07:00

Hansa Biopharma

Hansa Biopharma publicerar årsrapport och hållbarhetsredovisning för 2025 26 mar 07:00

Hansa Biopharma

Hansa Biopharma publishes 2025 Annual and Sustainability Reports 20 mar 08:00

Hansa Biopharma

Hansa Biopharma offentliggör finansiering om 30 miljoner USD genom konvertibla skuldebrev 20 mar 08:00

Hansa Biopharma

Hansa Biopharma announces a USD 30 million convertible note financing 13 mar 12:10

Hansa Biopharma

Hansa Biopharma presenterar vid Redeye Theme Event: Commercialization in Life Science 13 mar 12:10

Hansa Biopharma

Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science 10 mar 10:15

Hansa Biopharma

Hansa Biopharma deltar vid DNB Carnegie Healthcare Conference 2026 10 mar 10:15

Hansa Biopharma

Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026 09 mar 09:55

Hansa Biopharma

Hansa Biopharma deltar vid LSX Investival Showcase USA 09 mar 09:55

Hansa Biopharma

Hansa Biopharma participating at LSX Investival Showcase USA 06 mar 17:45

Hansa Biopharma

Hansa Biopharma deltar vid Leerink Global Healthcare Conference 06 mar 17:45

Hansa Biopharma

Hansa Biopharma participating at Leerink Global Healthcare Conference 04 mar 22:08

Hansa Biopharma

PDUFA Action Date for Hansa Biopharma’s Imlifidase BLA Set for December 19, 2026 04 mar 22:08

Hansa Biopharma

PDUFA-datum för Hansa Biopharmas ansökan om marknadsgodkännande för imlifidase fastställt till 19 december 2026 23 feb 17:00

Hansa Biopharma

Hansa Biopharma presenterar vid TD Cowen’s 46th Annual Health Care Conference 23 feb 17:00

Hansa Biopharma

Hansa Biopharma presenting at TD Cowen’s 46th Annual Health Care Conference 18 feb 19:53

Hansa Biopharma

Hansa Biopharmas ansökan för biologisk medicinsk produkt (BLA) för imlifidase har accepterats av FDA 18 feb 19:53

Hansa Biopharma

Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA 11 feb 07:00

Hansa Biopharma

Hansa Biopharma rapporterar finansiella resultat för fjärde kvartalet och helåret 2025 11 feb 07:00

Hansa Biopharma

Hansa Biopharma Reports Fourth Quarter and Full-Year 2025 Financial Results 26 jan 12:15

Hansa Biopharma

Hansa Biopharma bjuder in till en telefonkonferens för att presentera bokslutskommuniké för 2025 26 jan 12:15

Hansa Biopharma

Hansa Biopharma to host Year-end report 2025 conference call 22 jan 13:30

Hansa Biopharma

Hansa Biopharma har vunnit 2025 års SwedenBIO Award 22 jan 13:30

Hansa Biopharma

Hansa Biopharma has won the 2025 SwedenBIO Award 19 dec 2025 20:35

Hansa Biopharma

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation 19 dec 2025 20:35

Hansa Biopharma

Hansa Biopharma lämnar in BLA-ansökan till FDA för imlifidase för desensitisering vid njurtransplantation 19 dec 2025 11:45

Hansa Biopharma

Hansa Biopharma presenterar på den 44:e årliga J.P. Morgan Healthcare-konferensen 19 dec 2025 11:45

Hansa Biopharma

Hansa Biopharma presenting at 44th Annual J.P. Morgan Healthcare Conference 16 dec 2025 23:07

Hansa Biopharma

Hansa ger uppdatering om den registreringsgrundande fas 3-studien för anti-glomerulär basalmembransjukdom (anti-GBM)16 dec 2025 23:07

Hansa Biopharma

Hansa provides update on Pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease 15 dec 2025 07:00

Hansa Biopharma

Hansa Biopharma announce changes to strengthen European and International organisation 15 dec 2025 07:00

Hansa Biopharma

Hansa Biopharma gör förändringar för att stärka den europeiska och internationella organisationen 13 nov 2025 15:00

Hansa Biopharma

Hansa Biopharma presenterar vid Jefferies Global Healthcare Conference och DNB Carnegie’s 16th Annual Nordic Healthcare Conference 13 nov 2025 15:00

Hansa Biopharma

Hansa Biopharma presenting at Jefferies Global Healthcare Conference and DNB Carnegie’s 16th Annual Nordic Healthcare Conference 12 nov 2025 08:00

Hansa Biopharma

Upcoming KOL Call today: Insights on clinical practice and imlifidase Phase 3 Results 12 nov 2025 08:00

Hansa Biopharma

Kommande KOL-samtal idag: Insikter om klinisk praxis och fas 3- resultaten med imlifidase 05 nov 2025 11:00

Hansa Biopharma

Hansa at Truist Securities, Stifel, and SEB Healthcare conferences 05 nov 2025 11:00

Hansa Biopharma

Hansa deltar vid konferenserna Truist Securities, Stifel och SEB Healthcare 30 okt 2025 07:00

Hansa Biopharma

Hansa Biopharma redovisar finansiella resultat för tredje kvartalet och delårsperioden 2025 30 okt 2025 07:00

Hansa Biopharma

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results 29 okt 2025 18:00

Hansa Biopharma

Hansa arrangerar webcast med framstående transplantationskirurger: Insikter om klinisk praxis och fas 3- resultaten med imlifidase 29 okt 2025 18:00

Hansa Biopharma

Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results 10 okt 2025 10:00

Hansa Biopharma

Data från GNT-018-IDES-studien visar att imlifidase kan användas som förbehandling till genterapi för patienter med Criegler Najjars Syndrom och som har antikroppar mot AAV 10 okt 2025 10:00

Hansa Biopharma

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV 08 okt 2025 16:00

Hansa Biopharma

Hansa Biopharma to host Q3 2025 interim results conference call 08 okt 2025 16:00

Hansa Biopharma

Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q3 2025 07 okt 2025 17:00

Hansa Biopharma

Hansa Biopharma deltar i Optimums 17:e årliga Healthcare Investor Conference och Nordic Life Science Days 2025 07 okt 2025 17:00

Hansa Biopharma

Hansa Biopharma participating in Optimum’s 17th Annual Healthcare Investor Conference and at Nordic Life Science Days 2025 26 sep 2025 18:50

Hansa Biopharma

Genethon to present preliminary efficacy and safety data from Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 at ESGCT congress 2025 24 sep 2025 18:21

Hansa Biopharma

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation 24 sep 2025 18:21

Hansa Biopharma

Imlifidase når framgångsrikt primärt effektmått i den registreringsgrundande fas 3-studien ConfIdeS i USA för njurtransplantation 15 sep 2025 16:45

Hansa Biopharma

Hansa Biopharma Presenting at the Pareto 16 Annual Healthcare Conference 04 sep 2025 07:00

Hansa Biopharma

Hansa Biopharma to Participate in H.C. Wainwright 27th Annual Global Investment Conference 02 sep 2025 17:30

Hansa Biopharma

Bulletin from the Extraordinary General Meeting in Hansa Biopharma AB (publ)02 sep 2025 17:30

Hansa Biopharma

Kommuniké från extra bolagsstämma i Hansa Biopharma AB (publ)07 aug 2025 07:00

Hansa Biopharma

Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)07 aug 2025 07:00

Hansa Biopharma

Kallelse till extra bolagsstämma i Hansa Biopharma AB (publ)01 aug 2025 21:15

Hansa Biopharma

Hansa Biopharma tillkännager bekräftande resultat från behandling med imlifidase innan genterapibehandling för Duchennes muskeldystrofi 01 aug 2025 21:15

Hansa Biopharma

Hansa Biopharma announces supportive data from treatment with imlifidase prior to the administration of gene therapy for Duchenne muscular dystrophy 29 jul 2025 18:00

Hansa Biopharma

Hansa Biopharma announces key executive appointments to support continued growth 17 jul 2025 07:00

Hansa Biopharma

Hansa Biopharma Reports Second Quarter and Interim January-June 2025 Financial Results 17 jul 2025 07:00

Hansa Biopharma

Hansa Biopharma redovisar resultat för andra kvartalet och delårsperioden januari-juni 2025 08 jul 2025 08:00

Hansa Biopharma

Hansa Biopharma appoints Dr Richard Philipson as Chief Medical Officer 03 jul 2025 08:00

Hansa Biopharma

Hansa Biopharma to host Q2 2025 interim results conference call 03 jul 2025 08:00

Hansa Biopharma

Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q2 2025 30 jun 2025 08:00

Hansa Biopharma

Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London 30 jun 2025 07:00

Hansa Biopharma

Hansa Biopharma: Ökning av antalet aktier och röster 30 jun 2025 07:00

Hansa Biopharma

Hansa Biopharma: Increase in number of shares and votes 25 jun 2025 16:00

Hansa Biopharma

Kommuniké från årsstämma i Hansa Biopharma AB (publ)25 jun 2025 16:00

Hansa Biopharma

Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)11 jun 2025 08:40

Hansa Biopharma

Hansa Biopharma to attend BIO International Convention 09 jun 2025 08:00

Hansa Biopharma

Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025 26 maj 2025 18:40

Hansa Biopharma

Hansa Biopharma planerar omstrukturering för att optimera resursfördelning och förbättra operationell effektivitet 26 maj 2025 18:40

Hansa Biopharma

Hansa Biopharma plans restructuring to optimize resource allocation and improve operational efficiency 26 maj 2025 07:00

Hansa Biopharma

Kallelse till årsstämma i Hansa Biopharma AB (publ)26 maj 2025 07:00

Hansa Biopharma

Notice to Annual General Meeting in Hansa Biopharma AB (publ)14 maj 2025 08:00

Hansa Biopharma

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS 13 maj 2025 08:00

Hansa Biopharma

Hansa Biopharma utser Maria Törnsén till Chief Operating Officer och President U.S.13 maj 2025 08:00

Hansa Biopharma

Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.24 apr 2025 08:00

Hansa Biopharma

Hansa Biopharma redovisar resultat för första kvartalet och delårsperioden januari-mars 2025 24 apr 2025 08:00

Hansa Biopharma

Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results 24 apr 2025 07:00

Hansa Biopharma

Hansa Biopharma utser ny VD 24 apr 2025 07:00

Hansa Biopharma

Hansa Biopharma appoints new Chief Executive Officer 03 apr 2025 08:00

Hansa Biopharma

Hansa Biopharma to host Q1 2025 interim results conference call 03 apr 2025 08:00

Hansa Biopharma

Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2025 25 mar 2025 09:00

Hansa Biopharma

Hansa Biopharma to attend Van Lanschot Kempen Life Sciences Conference 21 mar 2025 15:00

Hansa Biopharma

Hansa Biopharma publishes 2024 Annual and Sustainability Reports 21 mar 2025 15:00

Hansa Biopharma

Hansa Biopharma publicerar årsredovisning och hållbarhetsredovisning för 2024 11 mar 2025 14:35

Hansa Biopharma

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients 04 mar 2025 08:00

Hansa Biopharma

Hansa Biopharma to attend Leerink Partners Global Healthcare Conference 24 feb 2025 08:00

Hansa Biopharma

Hansa Biopharma to attend TD Cowen Healthcare Conference 06 feb 2025 07:00

Hansa Biopharma

Hansa Biopharmas bokslutskommuniké för januari–december 2024 06 feb 2025 07:00

Hansa Biopharma

Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results 23 jan 2025 07:00

Hansa Biopharma

Hansa Biopharma to host Year-end report 2024 conference call 23 jan 2025 07:00

Hansa Biopharma

Hansa Biopharma bjuder in till en telefonkonferens för att presentera bokslutskommuniké för 2024 07 jan 2025 16:45

Hansa Biopharma

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference